Narinder S. Shargill

Narinder has more than 20 years of experience in taking medical devices through clinical development, regulatory approvals, and post-approval support through Medical Affairs’ activities, with 15 years of experience in interventional pulmonology. Prior to Pulmonx, Narinder was Vice President, Clinical Strategy and Medical Affairs–Pulmonary at Boston Scientific, where he played a key global role supporting the Alair® Bronchial Thermoplasty System. Previously, Narinder served as Vice President, Clinical Affairs at Asthmatx, where his efforts led to the approval of the first therapeutic device in the interventional pulmonology space. Earlier in his career, Narinder worked with Baxter following its acquisition of Fusion Medical Technologies, Nycomed Salutar, and Scios Inc. Narinder holds a PhD in Nutrition/Biochemistry from the University of Southampton, England, and completed his post-doctoral training jointly at the University of Southern California School of Medicine and School of Pharmacy.